Differential Expression of Biomarkers in Men and Women

Seminars in Oncology

Volumn 36, Issue 6, 2009, Pages 553-565

  Planchard, David ^a   Loriot, Yohann ^a   Goubar, Aicha ^a   Commo, Fréderic ^a   Soria, Jean Charles ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLIN B1; CYCLOOXYGENASE 1; CYTOCHROME P450 1A1; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GASTRIN RELEASING PEPTIDE; GEFITINIB; GEMCITABINE; GLUTATHIONE TRANSFERASE M1; MULTIDRUG RESISTANCE PROTEIN 1; ORNITHINE DECARBOXYLASE; PLACEBO; PROTEIN BAX; PROTEIN P53; PROTEIN RRM1; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; TOBACCO SMOKE; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; XRCC3 PROTEIN;

ARTICLE; CHEMICAL CARCINOGENESIS; CLINICAL TRIAL; FEMALE; GENE MUTATION; GENETIC MARKER; GENETIC POLYMORPHISM; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; ONCOGENE; ONCOGENE K RAS; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; VIRUS INFECTION; VIRUS TRANSMISSION; X CHROMOSOME; Y CHROMOSOME;

CARCINOMA, NON-SMALL-CELL LUNG; CYTOCHROME P-450 CYP1A1; FEMALE; GASTRIN-RELEASING PEPTIDE; GENE EXPRESSION; GLUTATHIONE TRANSFERASE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTORS, ESTROGEN; SEX FACTORS; SMOKING; TUMOR MARKERS, BIOLOGICAL; WOMEN'S HEALTH;

EID: 71049129446     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.09.004     Document Type: Article

References (103)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., and Thun M.J. Cancer statistics. 2007. CA Cancer J Clin 57 (2007) 43-66
2. Patel J.D., Bach P.B., and Kris M.G. Lung cancer in US women: a contemporary epidemic. JAMA 291 (2004) 1763-1768
3. Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., and Calle E.E. Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst 98 (2006) 691-699
4. Ferguson M.K., Skosey C., Hoffman P.C., and Golomb H.M. Sex-associated differences in presentation and survival in patients with lung cancer. J Clin Oncol 8 (1990) 1402-1407
5. Radzikowska E., Glaz P., and Roszkowski K. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20,561 cases. Ann Oncol 13 (2002) 1087-1093
6. Visbal A.L., Williams B.A., Nichols III F.C., Marks R.S., Jett J.R., Aubry M.C., et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 78 (2004) 209-215
7. Henschke C.I., Yip R., and Miettinen O.S. Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer. JAMA 296 (2006) 180-184
8. Zang E.A., and Wynder E.L. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 88 (1996) 183-192
9. Risch H.A., Howe G.R., Jain M., Burch J.D., Holowaty E.J., and Miller A.B. Are female smokers at higher risk for lung cancer than male smokers?. A case-control analysis by histologic type. Am J Epidemiol 138 (1993) 281-293
10. Kreuzer M., Boffetta P., Whitley E., Ahrens W., Gaborieau V., Heinrich J., et al. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br J Cancer 82 (2000) 227-233
11. Bach P.B., Kattan M.W., Thornquist M.D., Kris M.G., Tate R.C., Barnett M.J., et al. Variations in lung cancer risk among smokers. J Natl Cancer Inst 95 (2003) 470-478
12. Bain C., Feskanich D., Speizer F.E., Thun M., Hertzmark E., Rosner B.A., et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 96 (2004) 826-834
13. Wakelee H.A., Chang E.T., Gomez S.L., Keegan T.H., Feskanich D., Clarke C.A., et al. Lung cancer incidence in never smokers. J Clin Oncol 25 (2007) 472-478
14. Travis W.D., Lubin J., Ries L., and Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 77 (1996) 2464-2470
15. Thun M.J., Lally C.A., Flannery J.T., Calle E.E., Flanders W.D., and Heath Jr. C.W. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89 (1997) 1580-1586
16. Hemminki K. DNA adducts, mutations and cancer. Carcinogenesis 14 (1993) 2007-2012
17. Smith L.E., Denissenko M.F., Bennett W.P., Li H., Amin S., Tang M., et al. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 92 (2000) 803-811
18. Daniel V. Glutathione S-transferases: gene structure and regulation of expression. Crit Rev Biochem Mol Biol 28 (1993) 173-207
19. Mollerup S., Berge G., Baera R., Skaug V., Hewer A., Phillips D.H., et al. Sex differences in risk of lung cancer: expression of genes in the PAH bioactivation pathway in relation to smoking and bulky DNA adducts. Int J Cancer 119 (2006) 741-744
20. Seidegard J., Pero R.W., Miller D.G., and Beattie E.J. A glutathione transferase in human leukocytes as a marker for the susceptibility to lung cancer. Carcinogenesis 7 (1986) 751-753
21. Tang D.L., Rundle A., Warburton D., Santella R.M., Tsai W.Y., Chiamprasert S., et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis 19 (1998) 1949-1953
22. Dresler C.M., Fratelli C., Babb J., Everley L., Evans A.A., and Clapper M.L. Gender differences in genetic susceptibility for lung cancer. Lung Cancer 30 (2000) 153-160
23. Taioli E., and Wynder E.L. Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86 (1994) 869-870
24. Wei Q., Cheng L., Amos C.I., Wang L.E., Guo Z., Hong W.K., et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 92 (2000) 1764-1772
25. Grossman L., and Wei Q. DNA repair and epidemiology of basal cell carcinoma. Clin Chem 41 (1995) 1854-1863
26. O'Brien S.N., Larcom L.L., and Baxley E.G. Correlates of plasma cortisol and DNA repair in human peripheral lymphocytes: suppression of repair in women taking estrogen. Hormone Res 39 (1993) 241-246
27. Shriver S.P., Bourdeau H.A., Gubish C.T., Tirpak D.L., Davis A.L., Luketich J.D., et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J Natl Cancer Inst 92 (2000) 24-33
28. Keohavong P., DeMichele M.A., Melacrinos A.C., Landreneau R.J., Weyant R.J., and Siegfried J.M. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2 (1996) 411-418
29. Wang H., Jin G., Wang H., Liu G., Qian J., Jin L., et al. Genetic susceptibility of lung cancer associated with common variants in the 3′ untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. Cancer 115 (2009) 595-607
30. Cheng Y.W., Chiou H.L., Sheu G.T., Hsieh L.L., Chen J.T., Chen C.Y., et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 61 (2001) 2799-2803
31. Cheng Y.W., Lee H., Shiau M.Y., Wu T.C., Huang T.T., and Chang Y.H. Human papillomavirus type 16/18 up-regulates the expression of interleukin-6 and antiapoptotic Mcl-1 in non-small cell lung cancer. Clin Cancer Res 14 (2008) 4705-4712
32. Cheng Y.W., Wu M.F., Wang J., Yeh K.T., Goan Y.G., Chiou H.L., et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res 67 (2007) 10686-10693
33. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
34. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54 (1994) 4855-4878
35. Jassem E., Niklinski J., Rosell R., Niklinska W., Jakobkiewicz J., Monzo M., et al. Types and localisation of p53 gene mutations: a report on 332 non-small cell lung cancer patients. Lung Cancer 34 Suppl 2 (2001) S47-S51
36. Hainaut P., and Pfeifer G.P. Patterns of p53 G→T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 22 (2001) 367-374
37. Toyooka S., Tsuda T., and Gazdar A.F. The TP53 gene, tobacco exposure, and lung cancer. Hum Mutat 21 (2003) 229-239
38. Kure E.H., Ryberg D., Hewer A., Phillips D.H., Skaug V., Baera R., and Haugen A. p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels. Carcinogenesis 17 (1996) 2201-2205
39. Guinee Jr. D.G., Travis W.D., Trivers G.E., De Benedetti V.M., Cawley H., Welsh J.A., et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis 16 (1995) 993-1002
40. Riely G.J., Kris M.G., Rosenbaum D., Marks J., Li A., Chitale D.A., Nafa K., et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14 (2008) 5731-5734
41. Sun S., Schiller J.H., and Gazdar A.F. Lung cancer in never smokers-a different disease. Nature reviews 7 (2007) 778-790
42. Nelson H.H., Christiani D.C., Mark E.J., Wiencke J.K., Wain J.C., and Kelsey K.T. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J Natl Cancer Inst 91 (1999) 2032-2038
43. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
44. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
45. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23 (2005) 2513-2520
46. Yang S.H., Mechanic L.E., Yang P., Landi M.T., Bowman E.D., Wampfler J., et al. Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res 11 (2005) 2106-2110
47. Toyooka S., Matsuo K., Shigematsu H., Kosaka T., Tokumo M., Yatabe Y., et al. The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. Clin Cancer Res 13 (2007) 5763-5768
48. Bell D.W., Lynch T.J., Haserlat S.M., Harris P.L., Okimoto R.A., Brannigan B.W., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005) 8081-8092
49. Mitsudomi T., Kosaka T., and Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol Jpn Soc Clin Oncol 11 (2006) 190-198
50. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97 (2005) 339-346
51. Matsuo K., Ito H., Yatabe Y., Hiraki A., Hirose K., Wakai K., et al. Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. Cancer Sci 98 (2007) 96-101
52. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Franklin W.A., Dziadziuszko R., Thatcher N., et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24 (2006) 5034-5042
53. Zhu C.Q., da Cunha Santos G., Ding K., Sakurada A., Cutz J.C., Liu N., et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26 (2008) 4268-4275
54. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
55. Takano T., Ohe Y., Sakamoto H., Tsuta K., Matsuno Y., Tateishi U., et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23 (2005) 6829-6837
56. Hirsch F.R., Varella-Garcia M., Bunn Jr. P.A., Di Maria M.V., Veve R., Bremmes R.M., et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21 (2003) 3798-3807
57. Jeon Y.K., Sung S.W., Chung J.H., Park W.S., Seo J.W., Kim C.W., et al. Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer 54 (2006) 387-398
58. Hirsch F.R., Varella-Garcia M., McCoy J., West H., Xavier A.C., Gumerlock P., et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol 23 (2005) 6838-6845
59. Moulder S.L., Yakes F.M., Muthuswamy S.K., Bianco R., Simpson J.F., and Arteaga C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61 (2001) 8887-8895
60. Cappuzzo F., Varella-Garcia M., Shigematsu H., Domenichini I., Bartolini S., Ceresoli G.L., et al. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 23 (2005) 5007-5018
61. Hirsch F.R., Varella-Garcia M., Cappuzzo F., McCoy J., Bemis L., Xavier A.C., et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18 (2007) 752-760
62. Wakelee H.A., Wang W., Schiller J.H., Langer C.J., Sandler A.B., Belani C.P., et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol 1 (2006) 441-446
63. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
64. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
65. Albain K.S., Unger J., Gotay C.C., Davies A.M., Edelman M., Herbst R.S., et al. Toxicity and survival by sex in patients with advanced non-small cell lung carcinoma (NSCLC) on modern Southwest Oncology Group (SWOG) trials. J Clin Oncol 25 Suppl 18 (2007)
66. Olaussen K.A., Dunant A., Fouret P., Brambilla E., Andre F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 (2006) 983-991
67. Ceppi P., Volante M., Novello S., Rapa I., Danenberg K.D., Danenberg P.V., et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17 (2006) 1818-1825
68. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 (2002) 2286-2291
69. Zheng Z., Chen T., Li X., Haura E., Sharma A., and Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356 (2007) 800-808
70. Isla D., Felip E., Garrido P., Viñolas N., García-Campelo R., Lianes P., et al. Sex differences in non-small cell lung cancer (NSCLC) patients (p) participating in Spanish Lung Cancer Group (SLCG) trials. J Clin Oncol 25 Suppl 18 (2007)
71. Rosell R., Perez-Roca L., Sanchez J.J., Cobo M., Moran T., Chaib I., et al. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. PloS One 4 (2009) e5133
72. Boukovinas I., Papadaki C., Mendez P., Taron M., Mavroudis D., Koutsopoulos A., et al. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. PloS One 3 (2008) e3695
73. Danenberg K., Brabender J., Schneider S., Schneider P., Metzger R., and Danenberg P.V. Gender differences in the predictive power of prognostic factors in NSCLC. J Clin Oncol 22 Suppl 14 (2004)
74. Arinaga M., Noguchi T., Takeno S., Chujo M., Miura T., and Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97 (2003) 457-464
75. Arinaga M., Noguchi T., Takeno S., Chujo M., Miura T., Kimura Y., et al. Clinical implication of cyclin B1 in non-small cell lung cancer. Oncol Rep 10 (2003) 1381-1386
76. Stabile L.P., Davis A.L., Gubish C.T., Hopkins T.M., Luketich J.D., Christie N., et al. Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Res 62 (2002) 2141-2150
77. Hershberger P.A., Vasquez A.C., Kanterewicz B., Land S., Siegfried J.M., and Nichols M. Regulation of endogenous gene expression in human non-small cell lung cancer cells by estrogen receptor ligands. Cancer Res 65 (2005) 1598-1605
78. Cagle P.T., Mody D.R., and Schwartz M.R. Estrogen and progesterone receptors in bronchogenic carcinoma. Cancer Res 50 (1990) 6632-6635
79. Mollerup S., Jorgensen K., Berge G., and Haugen A. Expression of estrogen receptors alpha and beta in human lung tissue and cell lines. Lung Cancer 37 (2002) 153-159
80. Wu C.T., Chang Y.L., Shih J.Y., and Lee Y.C. The significance of estrogen receptor beta in 301 surgically treated non-small cell lung cancers. J Thorac Cardiovasc Surg 130 (2005) 979-986
81. Chlebowski R.T., Shwartz A., Wakelee H., Anderson G.L., Stefanick M.L., Manson J.E., et al. Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. J Clin Oncol 27 Suppl 18 (2009)
82. Yager J.D., and Liehr J.G. Molecular mechanisms of estrogen carcinogenesis. Ann Rev Pharmacol Toxicol 36 (1996) 203-232
83. Siegfried J.M. Women and lung cancer: does oestrogen play a role?. Lancet Oncol 2 (2001) 506-513
84. Dubey S., Siegfried J.M., and Traynor A.M. Non-small-cell lung cancer and breast carcinoma: chemotherapy and beyond. Lancet Oncol 7 (2006) 416-424
85. Stabile L.P., Lyker J.S., Gubish C.T., Zhang W., Grandis J.R., and Siegfried J.M. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65 (2005) 1459-1470
86. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., Gerald W.L., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14 (2008) 822-827
87. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 (2006) 570-580
88. Lee E.S., Son D.S., Kim S.H., Lee J., Jo J., Han J., et al. Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res 14 (2008) 7397-7404
89. Raponi M., Zhang Y., Yu J., Chen G., Lee G., Taylor J.M., et al. Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung. Cancer Res 66 (2006) 7466-7472
90. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A., et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 356 (2007) 11-20
91. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 8 (2002) 816-824
92. Broet P., Camilleri-Broet S., Zhang S., Alifano M., Bangarusamy D., Battistella M., et al. Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. Cancer Res 69 (2009) 1055-1062
93. Larsen J.E., Pavey S.J., Passmore L.H., Bowman R., Clarke B.E., Hayward N.K., et al. Expression profiling defines a recurrence signature in lung squamous cell carcinoma. Carcinogenesis 28 (2007) 760-766
94. Tibshirani R., Hastie T., Narasimhan B., and Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 99 (2002) 6567-6572
95. Ganesan S., Silver D.P., Greenberg R.A., Avni D., Drapkin R., Miron A., et al. BRCA1 supports XIST RNA concentration on the inactive X chromosome. Cell 111 (2002) 393-405
96. Kawakami T., Okamoto K., Sugihara H., Hattori T., Reeve A.E., Ogawa O., et al. The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors. J Urol 169 (2003) 1546-1552
97. Nygard O., and Nika H. Identification by RNA-protein cross-linking of ribosomal proteins located at the interface between the small and the large subunits of mammalian ribosomes. EMBO J 1 (1982) 357-362
98. Rocak S., and Linder P. DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 5 (2004) 232-241
99. Lau Y.F., and Zhang J. Expression analysis of thirty one Y chromosome genes in human prostate cancer. Mol Carcinog 27 (2000) 308-321
100. Foresta C., Ferlin A., Garolla A., Moro E., Pistorello M., Barbaux S., et al. High frequency of well-defined Y-chromosome deletions in idiopathic Sertoli cell-only syndrome. Hum Reprod 13 (1998) 302-307
101. Agger K., Cloos P.A., Christensen J., Pasini D., Rose S., Rappsilber J., et al. UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development. Nature 449 (2007) 731-734
102. Vawter M.P., Evans S., Choudary P., Tomita H., Meador-Woodruff J., Molnar M., et al. Gender-specific gene expression in post-mortem human brain: localization to sex chromosomes. Neuropsychopharmacology 29 (2004) 373-384
103. Tabernero M.D., Espinosa A.B., Maillo A., Rebelo O., Vera J.F., Sayagues J.M., et al. Patient gender is associated with distinct patterns of chromosomal abnormalities and sex chromosome linked gene-expression profiles in meningiomas. Oncologist 12 (2007) 1225-1236